概括
最近的进展为慢性失眠提供了新的非药物和药物治疗方法,这是一种影响健康和经济的常见疾病. 本综述涵盖了这些新的治疗策略,以及对失眠管理的现有选择.
科学领域:
- 睡眠医学 睡眠医学
- 神经学 神经学
- 精神病学是一个精神病学.
背景情况:
- 失眠是一种普遍存在的睡眠障碍,对健康和社会经济产生重大影响.
- 之前的慢性失眠治疗方案显示进展有限.
- 近年来,人们在治疗慢性失眠方面取得了突破性进展.
研究的目的:
- 审查慢性失眠的非药物和药物治疗的最新进展.
- 在既定治疗范式中将新的治疗方法置于背景中.
- 提供关于目前和新兴的失眠管理策略的概述.
主要方法:
- 关于不眠症治疗的最新研究的文献综述.
- 综合关于新型非药物治疗的发现.
- 对慢性失眠的新药物干预措施的分析.
主要成果:
- 对于慢性失眠,有前途的新型非药物治疗方法正在出现.
- 新型药理疗法显示出提高疗效和安全性的潜力.
- 整合新的和既定的治疗方法提供了一个全面的管理策略.
结论:
- 最近的治疗进展为慢性失眠患者带来了新的希望.
- 更新和传统治疗的组合可以优化患者的治疗结果.
- 持续的研究对于进一步完善失眠管理策略至关重要.
相关概念视频
Management of Insomnia
260
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
260
Insomnia
88
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
88
Sedatives and Hypnotics Drugs: Miscellaneous Agents
183
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
183
Sedatives and Hypnotics: Overview
410
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
410
CNS Depressants: Barbiturates and Benzodiazepines
290
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
290
Narcolepsy
119
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
119


